LL-37 and VIP Interaction: Compatible | Peptide Database

FDA-approved for treatment of essential hypertension as monotherapy or in combination with other antihypertensives. Provides consistent 24-hour blood pressure reduction. Particularly effective for AAS-induced hypertension where elevated blood pressure is driven by RAAS activation and increased erythropoiesis. FDA-approved for reduction of cardiovascular morbidity in patients at high risk. The ONTARGET trial demonstrated non-inferiority to ramipril for the composite of cardiovascular death, MI, stroke, and hospitalization for heart failure in over 25,000 high-risk patients. Angiotensin II receptor blockade counteracts the pro-hypertrophic and pro-fibrotic effects of supraphysiological androgen levels on the myocardium. Preclinical and observational data support the use of ARBs to attenuate left ventricular hypertrophy in steroid users. Widely recommended in harm reduction protocols. Reduces intraglomerular pressure and proteinuria by blocking angiotensin II-mediated efferent arteriolar constriction. Slows progression of chronic kidney disease, particularly in patients with diabetic nephropathy or hypertensive nephrosclerosis. Relevant for AAS users where elevated blood pressure and NSAID co-use may compromise renal function. Telmisartan's partial PPAR-gamma agonism improves insulin sensitivity without the weight gain associated with full PPAR-gamma agonists like pioglitazone. May reduce the risk of new-onset diabetes in hypertensive patients. The metabolic benefit is particularly relevant for users of compounds that impair glucose tolerance (e.g., growth hormone, trenbolone).

The 2019 Isenmann et al. study at Freie Universitat Berlin demonstrated that ecdysterone supplementation (administered as spinach extract standardized to ecdysterone content) produced significantly greater increases in lean muscle mass compared to placebo over 10 weeks of resistance training in young, trained men. The highest-dose group gained approximately 2 kg more lean mass than placebo. These results, combined with earlier Soviet-era research and multiple animal studies, support ecdysterone as a meaningful natural anabolic agent. Participants in the Berlin study also showed greater improvements in one-repetition maximum bench press compared to placebo. Animal studies have demonstrated improved grip strength, endurance capacity, and force production with ecdysterone administration. The mechanism likely involves both increased muscle protein synthesis and improved calcium handling within muscle fibers, enhancing contractile efficiency. Preclinical evidence suggests ecdysterone accelerates recovery from exercise-induced muscle damage through anti-inflammatory effects and enhanced protein synthesis rates. Users frequently report reduced delayed-onset muscle soreness (DOMS) and improved training frequency tolerance. However, dedicated human recovery studies are limited. By promoting lean mass accretion without androgenic hormonal disruption, ecdysterone may support body recomposition (simultaneous fat loss and muscle gain) particularly in trained individuals on a structured nutrition plan. Some animal data suggest mild lipolytic effects, though this has not been convincingly demonstrated in human trials.